The Latest Breaking News from Ulcerative Colitis

Here's a roundup of top developments in the biotech space over the last 24 hours.

Connect Biopharma Holdings Limited (NASDAQ:CNTB) announced topline results at 12 weeks from its Phase 2 trial for CBP-307 (CBP-307CN002) for ulcerative colitis. CBP-307 0.2 mg demonstrated a numerical reduction for the primary endpoint of least squares mean change from baseline in adapted Mayo Score at Week 12 that did not meet statistical significance. …

Protagonist Therapeutics (NASDAQ: PTGX) announced top-line results from the Phase 2 IDEAL clinical study evaluating PN-943 in patients with moderate-to-severe ulcerative colitis (UC).

Applied Molecular Transport Inc (NASDAQ:AMTI) announced Phase 2 topline results from the FILLMORE monotherapy trial for AMT-101 in chronic pouchitis. Pouchitis is inflammation in the lining of a pouch created during surgery to treat ulcerative colitis or certain other diseases. The trial demonstrated that 36.4% (8/22) of patients achieved stool frequency response.  Rapid…

Gossamer Bio Inc (NASDAQ:GOSS) shares are falling after announcing topline results from its Phase 2 SHIFT-UC Study trial of GB004 in patients with mild-to-moderate active ulcerative colitis (UC). Neither GB004 treatment arm met the primary or secondary endpoints at week 12.  Gossamer will terminate the ongoing treat-through and open-label extension portions of the…

Megan McNeil was diagnosed with Ulcerative Colitis after she experienced symptoms such as passing blood when going to the bathroom